- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 9
The Center for Biosimilars® recaps the top stories for the week of September 9, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 9, 2019.
Number 5: Genentech has reached an agreement with JHL Biotech in a civil lawsuit related to trade secret theft. Under the agreement, JHL will have to destroy its biosimilar cell lines.
Number 4: The European Patent Office did not grant Alexion its request for 2 patents on Soliris.
Number 3: Celltrion has announced that its trastuzumab biosimilar, Herzuma, has received authorization from Health Canada.
Number 2: Patient organizations for those with inflammatory bowel disease are voicing concern about British Columbia’s plan to transition patients to biosimilars.
Number 1: A new report released Monday by UnitedHealth Group finds that administering specialty drugs outside of hospitals could save $4 billion each year.
Finally, last week, our e-newsletter asked what you think is the greatest challenge facing biosimilars in the United States.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
